s'authentifier
version française rss feed
HAL : hal-00452864, version 1

Fiche détaillée  Récupérer au format
Annals of Oncology 20, 1 (2009) 110-6
L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature.
Arnaud Jaccard1, B. Petit2, S. Girault3, F. Suarez, R. Gressin, J.-M. Zini, V. Coiteux, C. Larroche, A. Devidas, C. Thiéblemont, P. Gaulard, B. Marin4, Nathalie Gachard1, Dominique Bordessoule2, 5, 6, O. Hermine7
(01/2009)

BACKGROUND: Extranodal natural killer (NK)/T-cell lymphoma, nasal type, and aggressive NK-cell leukemia are highly aggressive diseases with a poor outcome. PATIENTS AND METHODS: We report a multicentric French retrospective study of 15 patients with relapsed, refractory, or disseminated disease, treated with L-asparaginase-containing regimens in seven French centers. Thirteen patients were in relapse and/or refractory and 10 patients were at stage IV. RESULTS: All but two of the patients had an objective response to L-asparaginase-based treatment. Seven patients reached complete remission and only two relapsed. CONCLUSION: These data, although retrospective, confirm the excellent activity of L-asparaginase-containing regimens in refractory extranodal NK/T-cell lymphoma and aggressive NK-cell leukemia. Therefore, L-asparaginase-based regimen should be considered as a salvage treatment, especially for patients with disseminated disease. First-line L-asparaginase combination therapy for extranodal NK/T-cell lymphoma and aggressive NK-cell leukemia should be tested in prospective trials.
1 :  PMRIL - Physiologie moléculaire de la réponse immune et des lymphoproliférations
2 :  Faculté de Médecine
3 :  SUBATECH - Laboratoire SUBATECH Nantes
4 :  GEGENA2 - Groupe d'Étude sur les Géomatériaux et Environnements Naturels, Anthropiques et Archéologiques
5 :  Laboratoire d'hématologie
6 :  Service d'Hématologie Clinique et thérapie cellulaire
7 :  CHRI - Cytokines, hématopoïèse et réponse immune
Sciences du Vivant/Immunologie